Evidence map›Paper›PMID 37646153›Full record

ArticleCell transplantation

Mild Acute Graft-Versus-Host Disease Improves Outcomes After HLA-Haploidentical-Related Donor Transplantation Using Posttransplant Cyclophosphamide and Cord Blood Transplantation.

Fumiya Wada, Junya Kanda, Kimimori Kamijo, Masashi Nishikubo, Satoshi Yoshioka, Takayuki Ishikawa, Yasunori Ueda, Takashi Akasaka, Yasuyuki Arai, Kiyotaka Izumi and 18 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 17 institutions in 1 country.

Fumiya WadaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0001-6039-146X
Junya KandaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0002-6704-3633
Kimimori KamijoDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
Masashi NishikuboDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
Satoshi YoshiokaDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
Takayuki IshikawaDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
Yasunori UedaDepartment of Hematology/Oncology, Kurashiki Central Hospital, Okayama, Japan.
Takashi AkasakaDepartment of Hematology, Tenri Hospital, Tenri, Japan.
Yasuyuki AraiDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kiyotaka IzumiDepartment of Hematology, Kansai Electric Power Hospital, Osaka, Japan.
Hirokazu HirataDepartment of Hematology, Kansai Electric Power Hospital, Osaka, Japan.
Takashi IkedaDivision of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center, Shizuoka, Japan.
Akihito YonezawaDepartment of Hematology, Kokura Memorial Hospital, Fukuoka, Japan.
Naoyuki AnzaiDepartment of Hematology, Takatsuki Red Cross Hospital, Osaka, Japan.
Mitsumasa WatanabeDepartment of Hematology, Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Japan.
Kazunori ImadaDepartment of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
Kazuhiro YagoDepartment of Hematology, Shizuoka General Hospital, Shizuoka, Japan.
Naoki TamuraDepartment of Hematology, Kyoto City Hospital, Kyoto, Japan.
Mitsuru ItohDepartment of Hematology, Kyoto City Hospital, Kyoto, Japan.
Yuki MasuoDepartment of Hematology and Immunology, Japanese Red Cross Otsu Hospital, Shiga, Japan.
Akane KunitomiDepartment of Hematology and Immunology, Japanese Red Cross Otsu Hospital, Shiga, Japan.
Tomoharu TakeokaDepartment of Hematology and Immunology, Japanese Red Cross Otsu Hospital, Shiga, Japan.
Toshiyuki KitanoDepartment of Hematology, Kitano Hospital, Osaka, Japan.
Nobuyoshi ArimaDepartment of Hematology, Shinko Hospital, Hyogo, Japan.
Masakatsu HishizawaDepartment of Hematology, Kyoto-Katsura Hospital, Kyoto, Japan.
Kohsuke AsagoeDepartment of Hematology, Shiga General Hospital, Shiga, Japan.
Tadakazu KondoDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Akifumi Takaori-KondoDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kyoto University · JPKobe City Medical Center General Hospital · JPOtsu Red Cross Hospital · JPKansai Electric Power Hospital · JPKyoto City Hospital · JPOsaka Hospital · JPHyogo Prefectural Amagasaki General Medical Center · JPKitano Hospital · JPKokura Memorial Hospital · JPKurashiki Central Hospital · JPKyoto Katsura Hospital · JPShiga Medical Center · JPShinko Hospital · JPShizuoka Cancer Center · JPShizuoka General Hospital · JPTakatsuki Red Cross Hospital · JPTenri Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Haploidentical-related donor transplantation using posttransplant cyclophosphamide (PTCy-haplo) and cord blood transplantation (CBT) are valid alternatives for patients with hematological malignancies when HLA-matched donor transplantation (MDT) is unavailable. However, the effects of graft-versus-host disease (GVHD) on outcomes after these transplants have not been fully elucidated. Therefore, we evaluated the effects of acute and chronic GVHD on transplant outcomes after PTCy-haplo transplants and compared them with CBT and MDT. We included a total of 914 adult patients with hematological malignancies in the Kyoto Stem Cell Transplantation Group registry who received PTCy-haplo (N = 120), CBT (N = 402), and MDT (N = 392), and achieved neutrophil engraftment. A multivariate analysis revealed that grade I-II acute GVHD improved of overall survival (OS) after PTCy-haplo [hazard ratio (HR) = 0.39,

Indexed as

Bronchiolitis Obliterans SyndromeCord Blood Stem Cell TransplantationGraft vs Host DiseaseHematologic NeoplasmsHematopoietic Stem Cell TransplantationAdultCyclophosphamideHumansRetrospective StudiesTransplantation ConditioningCyclophosphamideacute graft-versus-host diseasechronic graft-versus-host diseasecord blood transplantationhaploidenticalhematological malignanciesposttransplant cyclophosphamide

Identifiers

PMID37646153
PMCPMC10469234
OpenAlexW4386272415

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.